Anton C. Krucky, Co-Founder, Director, President and Chief Executive Officer. Mr. Krucky brings to Tissue Genesis decades of management that include product development, marketing, and sales experience in a global company, IBM. Prior to leaving IBM, he held several senior management positions including General Manager of Operations for IBM in the Pacific. Mr. Krucky has consulted to and invested in small and emerging technology businesses, and has personally owned several small businesses. He serves on the Boards of major corporations in the State of Hawaii that include Servco Pacific, in addition to key non-profit medical and healthcare Boards that include the University of Hawaii’s John A. Burns School of Medicine and the Pacific Health Research Institute. Mr. Krucky supports numerous community organizations and is an established business leader in Hawaii, bringing valuable contacts and relationships to TGI.

Thomas F. Cannon, Co-Founder, Director, Executive Vice President, Research and Development. Mr. Cannon is a co-inventor of the Bio-Optimization System, a co-founder of Tissue Genesis and the former President/founder of Bio-Optima. As a former program manager and space hardware developer for the highly successful Cell Culture Module (CCM) experiments series for NASA, Department of Defense, and NIH, he pioneered early versions of the BOS systems fourteen Space Shuttle missions in the 1990’s. He has extensive experience working with military hospitals, and has an established network of government contacts, medical contacts and bioengineering industry connections. Mr. Cannon is responsible for bringing together key technology assets and relationships with technology providers, leading researchers, and end users to TGI.

Bradley S. Perkins, Senior Vice President, Administration and General Counsel. Mr. Perkins has been the Vice President and General Counsel of a number of Silicon Valley companies, including Valence Technology, Mission West Properties, Alliance Semiconductor, and Hyperion Solutions Corporation. He was also a member of the legal departments of Xerox Corporation, Hewlett-Packard company, Ampex Corporation and VLSI Technology, and was counsel to Goodsill Anderson Quinn & Stifel. Mr. Perkins is responsible for all legal and intellectual property issues, as well as the company’s administrative functions. He has a BSE in electrical engineering from Duke University, and a Juris Doctorate from the McGeorge School of Law at the University of the Pacific, and is registered to practice in Hawaii, California, and before the United States Patent and Trademark Office.

Rex Chang, M.D., Director of Business Development. Dr. Chang has expertise and training in the life sciences and healthcare sectors.  Prior to joining Tissue Genesis, Dr. Chang consulted in the healthcare sector in emerging markets and did many years of legal work for global life science companies.  Dr. Chang is a trained attorney, and physician.  Dr. Chang received his J.D. degree from the Boalt Hall School of Law at UC Berkeley, and his M.D. degree from New York University’s School of Medicine, where he also trained in Radiology.  Dr. Chang also earned an accelerated M.B.A. degree from U.S.C.’s Marshall School of Business.  Dr. Chang earned his undergraduate degree in biology at The Johns Hopkins University.  Dr. Chang is licensed to practice law in California and New York.

Kerry Nagai, Director of Finance. Ms. Nagai is a Certified Public Accountant licensed in the State of Hawaii, but not currently in the practice of public accountancy.  She was previously an audit manager and professional development director at Deloitte and Touche LLP and specialized in the government, public, and insurance sectors.  She also worked for Alexander & Baldwin, Inc., the State of Hawaii Office of the Auditor,  and the Board of Education.  Ms. Nagai is responsible for managing the finance and accounting department and the financial reporting for the Company.  She has a BBA from the University of Hawaii at Manoa.

Michael Scott, Director of Quality and Regulatory Affairs. Mr. Scott brings to the Company an extensive resume of developing, implementing and guiding Quality and Regulatory Compliance Systems for companies in the medical field.  Over the past 16 years he has held quality management and quality engineering positions at Abbott Laboratories, Hospira, LabNow and Psi Health Solutions.  Mr. Scott holds a bachelor’s degree in Biology, a Master’s degree in Quality Systems Management and is a member of the College of Natural Sciences Advisory Council for the University of Texas at Austin.

Science and Technology Development Team

Stuart Williams, Ph.D., Chief Science Officer. Dr. Williams is Scientific Director of the Cardiovascular Innovation Institute at the University of Louisville School of Medicine. He is recognized internationally as an expert in vascular biology and vascular tissue engineering, and is a leader in endothelial cell isolation technology. He developed and patented the technique of isolating human endothelial cells and pluripotent stem cells from fat tissue obtained through liposuctions, currently licensed by Tissue Genesis through Thomas Jefferson University.

Gary D. Gentzkow, M.D., Chief Medical Officer.  Dr. Gentzkow heads the company’s efforts to move its research programs in adipose (fat) derived cells into clinical studies.  Dr. Gentzkow has 30 years experience developing new medical therapies – pharmaceutical, medical devices, biological and cellular.  For the past 20 years, Dr. Gentzkow’s research has focused on cellular therapies, including engineered human tissues, a field in which he has lectured and published extensively.  This work has focused on wound healing and cardiovascular regeneration and repair, and he has been a consultant to companies developing these new technologies.  From 1992 to 2006, at Advanced Tissue Sciences and Smith & Nephew, Dr. Gentzkow headed  the clinical research programs for the tissue-engineered human tissues, Dermagraft® and TransCyte®, dermal tissues approved for diabetic foot ulcers and burns respectively.  He also participated in research programs on cartilage, blood vessels, and cardiovascular regeneration.  Dr. Gentzkow is also the CMO for Theregen, Inc., conducting clinical studies utilizing this tissue-engineered human tissue technology, under the name of Anginera™, for cardiac regeneration.  Additionally, his work has included clinical studies on antiarrhythmic drugs, fibroblast growth factor for venous stasis and diabetic ulcers, and electrical stimulation for healing pressure ulcers.  He has published numerous articles and presented extensively in the field of wound healing and cardiovascular medicine around the world. Dr. Gentzkow received his A.B. degree cum laude from Harvard University and earned his M.D. degree from the University of Oregon Health Sciences Center and trained in Internal Medicine.

Paul Kosnik, Ph.D., Vice President, Research and Development, and Principal Investigator. Dr. Kosnik is Tissue Genesis’ Principal Investigator for Federal Grants and leads the Tissue Genesis team in innovations of proprietary intellectual property. His research and development efforts have been focused on tissue engineering and biochamber design, specifically hardware, software and instrumentation that emulate in vivo environments for medical applications of cell and tissue culture products. He has received four patents in the fields of tissue engineering and biochamber design and has authored five peer-reviewed manuscripts and three book chapters on functional tissue engineering. Dr. Kosnik is a member of the Tissue Engineering Society International and the International Society for Cellular Therapy. He serves as an adjunct assistant professor at Brown University, a visiting scientist in the Harvard-MIT Division of Human Sciences and Technology and is a member of the External Advisory Board for the University of North Carolina at Chapel Hill.

Kevin Lye, M.D., Director, Clinical Research. Dr. Lye leads the efforts of Tissue Genesis to develop the product interface and methodology for clinicians—from varied disciplines—who use the company's technology.   Exploration of, and application to, new fields of use also play a large role in his responsibilities.  Dr. Lye comes to Tissue Genesis with ten years of experience in post-graduate training, including a research fellowship at Yale University.  He has authored or co-authored over 25 publications on topics including novel therapies for carcinoid disease, refrozen botulinum toxin efficacy, abdominal wound closure devices, and gastric stem cells.  Dr. Lye has been privileged to have previously worked in the laboratories of James D. Otvos, Ph.D., founder of LipoMed, Inc.; Louis Argenta, M.D., inventor of negative pressure wound therapy devices used worldwide to heal complex wounds; and Irvin M. Modlin, M.D., Ph.D., a widely renowned innovator and director of the Gastric Pathobiology Research Group at Yale.  He has been an invited speaker to multiple international conferences, and over 60 presentations relating to his research projects have been made around the world in various venues.  After receiving his undergraduate degrees summa cum laude from North Carolina State University, including B.S. degrees in mathematics, biochemistry, and biological sciences, as well as a B.A. in chemistry, Dr. Lye earned his M.D. degree from Wake Forest University School of Medicine.

H. Joon Paek, Ph.D., Scientist. Dr. Paek is an expert in cell replacement therapy for diabetes and cartilage degeneration. He will lead the company’s research and development in regenerative cell-based medicine, with special focus on ligaments and diabetes. He received his Ph.D. in Biology from Brown University, a Masters of Engineering in Polymer Chemistry from Kyoto University in Japan, and his undergraduate degree in Chemistry from the College of William and Mary.

Michelle Stein, Ph.D., Scientist. Dr. Stein, with expertise in cell biology, molecular biology, and biochemistry focuses on technical writing and biomedical research toward our vascular and ligament project efforts.  Dr. Stein received her PhD in biomedical science from the Medical University of South Carolina and Bachelor of Science from Virginia Commonwealth University.  She has held such appointments as Visiting Scholar at University of California, San Diego as well as an Adjunct Faculty position at Coastal Carolina University.  She is currently a member of the Tissue Engineering and Regenerative Medicine International Society (TERMIS) and the International Fat Applied Technology Society (IFATS).

Erik Vossman, Director of Product Development. Mr. Vossman is the co-inventor of the mini-BOS, the Tissue Genesis Cell Isolation System, and pre- and post-processing  peripherals. He provides product development expertise from concept to manufacturing to regulatory submission, as well as supply chain management. A graduate of the University of Michigan’s bioengineering program, he brings advanced biology and engineering expertise to the present and emerging Company systems.